Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jay Hoofnagle, M.D., National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00475176
First received: May 17, 2007
Last updated: May 31, 2013
Last verified: May 2013
Results First Received: May 1, 2012  
Study Type: Interventional
Study Design: Endpoint Classification: Pharmacodynamics Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Chronic Hepatitis C
Interventions: Drug: Peginterferon alfa-2a
Drug: Ribavirin
Drug: S-adenosyl methionine for Chronic Liver Disease

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Twenty-four patients were enrolled at National Institutes of Health Clinic Center between October 2007 and April 2009.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Hepatitis C Treated With Peginterferon and Ribavirin Patients infected with hepatitis C virus (HCV) treated with peginterferon alpha-2a and ribavirin. After screening evaluation, patients will receive a first course of 2 weeks of peginterferon alfa-2a (180 micrograms weekly) and ribavirin (1000-1200 mg daily) during which symptoms, routine laboratory tests, HCV RNA levels, natural killer (NK) cell activity, and lymphocyte interferon-signaling responses will be monitored. After a 4-week washout period, patients will start SAMe (800 mg twice daily) for 2 weeks and then begin a second course of peginterferon and ribavirin in the same doses with similar monitoring. Therapy will be continued for at least 12 weeks, and patients with an early viral response will continue for a full 48 weeks.

Participant Flow:   Overall Study
    Hepatitis C Treated With Peginterferon and Ribavirin
STARTED   24 
COMPLETED   20 
NOT COMPLETED   4 
Adverse Event                2 
Withdrawal by Subject                1 
Protocol Violation                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Hepatitis C Treated With Peginterferon and Ribavirin Patients infected with hepatitis C virus (HCV) treated with peginterferon alpha-2a and ribavirin

Baseline Measures
   Hepatitis C Treated With Peginterferon and Ribavirin 
Overall Participants Analyzed 
[Units: Participants]
 24 
Age 
[Units: Year]
Median (Full Range)
 52.5 
 (41 to 65) 
Gender 
[Units: Participants]
 
Female   8 
Male   16 
Race/Ethnicity, Customized [1] 
[Units: Participants]
 
Hispanic   1 
Black   2 
White   21 
[1] Race
Body Mass Index 
[Units: Kg/m^2]
Mean (Standard Deviation)
 27.2  (3.74) 
Ishak Fibrosis [1] 
[Units: Units on a scale]
Median (Full Range)
 2 
 (0 to 6) 
[1] Possible range is 0 to 6. Higher values represent worse outcomes.
Cirrhosis 
[Units: Participants]
 
Cirrhosis   5 
Non-Cirrhosis   19 
Previous Therapy 
[Units: Participants]
 
Interferon/ribavirin   3 
Peginterferon/ribavirin   21 
Baseline HCV RNA Level 
[Units: Log10 (IU/mL)]
Mean (Standard Deviation)
 6.3  (0.6) 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Improvement in Viral Kinetics During the First 2 Weeks of Therapy   [ Time Frame: Days 7 to 14 of therapy ]

2.  Secondary:   2-log Decline in HCV RNA by Week 12 (Early Virological Response) and Sustained Eradication of HCV RNA (Sustained Virological Response).   [ Time Frame: 12 weeks from start of therapy ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats


  More Information